Zhejiang Haisen Pharmaceutical Co., Ltd. (SHE:001367)
China · Delayed Price · Currency is CNY 20.44
-1.36 (-6.24%)
At close: Aug 24, 2026
SHE:001367 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 540.88 | 531.67 | 470.54 | 396.28 | 421.14 | 386.79 |
Other Revenue | 0.18 | 0.59 | 0.97 | 1.17 | 1.64 | 2.19 |
| 541.06 | 532.26 | 471.51 | 397.45 | 422.78 | 388.98 | |
Revenue Growth | 7.58% | 12.88% | 18.63% | -5.99% | 8.69% | 36.58% |
Cost of Revenue | 290.07 | 291.24 | 281.91 | 237.4 | 266.52 | 236.12 |
Gross Profit | 251 | 241.02 | 189.6 | 160.05 | 156.26 | 152.87 |
Selling, General & Admin | 55.01 | 52.24 | 40.65 | 35.72 | 32.25 | 32.94 |
Research & Development | 39.35 | 38.86 | 27.78 | 18.84 | 15.77 | 12.07 |
Other Operating Expenses | 4.86 | 4.58 | 4.36 | 4.16 | 2.13 | 3.11 |
Operating Expenses | 101.53 | 98.41 | 72.88 | 59.15 | 51.24 | 47.85 |
Operating Income | 149.47 | 142.61 | 116.72 | 100.9 | 105.02 | 105.02 |
Interest Expense | -0.17 | -0.35 | -0.37 | -0.03 | -0.07 | -0.1 |
Interest & Investment Income | 9.1 | 10.7 | 18.41 | 15.62 | 3.55 | 2.25 |
Currency Exchange Gain (Loss) | -1.11 | -0.05 | 3.32 | 0.87 | 8.37 | -2.17 |
Other Non Operating Income (Expenses) | 0.11 | -0.28 | -0.24 | -0.19 | 0.05 | -0.4 |
EBT Excluding Unusual Items | 157.4 | 152.62 | 137.85 | 117.17 | 116.93 | 104.59 |
Gain (Loss) on Sale of Investments | 1.7 | 1.7 | - | - | -3.85 | 0.74 |
Gain (Loss) on Sale of Assets | -0.12 | - | - | -0.24 | - | - |
Asset Writedown | -0.32 | -0.4 | -1.23 | -0.96 | -1.21 | -0.67 |
Other Unusual Items | 2.54 | 2.84 | 5.11 | 4.71 | 11.91 | 3.86 |
Pretax Income | 161.2 | 156.76 | 141.79 | 120.68 | 123.78 | 108.52 |
Income Tax Expense | 20.38 | 20.88 | 19.23 | 16.01 | 16.19 | 14.52 |
Net Income | 140.82 | 135.88 | 122.56 | 104.67 | 107.59 | 94 |
Net Income to Common | 140.82 | 135.88 | 122.56 | 104.67 | 107.59 | 94 |
Net Income Growth | 12.38% | 10.87% | 17.09% | -2.72% | 14.46% | 49.62% |
Shares Outstanding (Basic) | 150 | 149 | 149 | 137 | 112 | 112 |
Shares Outstanding (Diluted) | 153 | 153 | 149 | 137 | 112 | 112 |
Shares Change | 0.68% | 2.15% | 9.03% | 22.74% | -0.02% | - |
EPS (Basic) | 0.94 | 0.91 | 0.82 | 0.76 | 0.96 | 0.84 |
EPS (Diluted) | 0.92 | 0.89 | 0.82 | 0.76 | 0.96 | 0.84 |
EPS Growth | 11.61% | 8.54% | 7.40% | -20.74% | 14.68% | 49.60% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 125.88 | 25.19 | 102.41 | 23.17 | 54.76 | 73.72 |
Free Cash Flow Per Share | 0.82 | 0.17 | 0.69 | 0.17 | 0.49 | 0.66 |
Dividend Per Share | 0.116 | 0.116 | 0.170 | 0.228 | - | - |
Dividend Growth | -31.77% | -31.77% | -25.50% | - | - | - |
Gross Margin | 46.39% | 45.28% | 40.21% | 40.27% | 36.96% | 39.30% |
Operating Margin | 27.63% | 26.79% | 24.75% | 25.39% | 24.84% | 27.00% |
Profit Margin | 26.03% | 25.53% | 25.99% | 26.33% | 25.45% | 24.16% |
Free Cash Flow Margin | 23.27% | 4.73% | 21.72% | 5.83% | 12.95% | 18.95% |
EBITDA | 175.21 | 164.28 | 132.04 | 113.52 | 118.59 | 117.37 |
EBITDA Margin | 32.38% | 30.87% | 28.00% | 28.56% | 28.05% | 30.17% |
D&A For EBITDA | 25.74 | 21.68 | 15.32 | 12.62 | 13.56 | 12.35 |
EBIT | 149.47 | 142.61 | 116.72 | 100.9 | 105.02 | 105.02 |
EBIT Margin | 27.63% | 26.79% | 24.75% | 25.39% | 24.84% | 27.00% |
Effective Tax Rate | 12.64% | 13.32% | 13.56% | 13.26% | 13.08% | 13.38% |
Revenue as Reported | 290.17 | 532.26 | 471.51 | 397.45 | 422.78 | 388.98 |